BioMAS

Company Overview

Snapshot

Founded in September 2000, BioMAS operates with 1–10 employees and has raised $2 million across one funding round. A significant milestone occurred in March 2014 when Cosmo Pharmaceuticals acquired a 15.4% stake in the company for ILS 7 million.

Business overview

BioMAS Ltd is a clinical-stage Health Tech & Life Sciences company focused on the invention, development, and commercialization of tellurium-based compounds. Its core products, AS101 and SAS, are small tellurium-based compounds designed to treat various conditions by targeting integrin-inhibitory properties. The company serves the pharmaceutical and healthcare industries, with its drugs demonstrating preclinical and clinical efficacy for autoimmune-inflammatory diseases, certain viral conditions, angiogenesis-related diseases, thrombocytopenia, neutropenia, and fertility preservation following chemotherapy and radiotherapy, primarily in the United States market.

Company Intelligence Q&A

What is BioMAS's primary focus?

BioMAS is a clinical-stage company specializing in the invention, development, and commercialization of tellurium-based compounds for various medical conditions.

What are the lead molecules developed by BioMAS?

The company's lead molecules are AS101 and SAS, which are small tellurium-based compounds with integrin-inhibitory properties.

What conditions do BioMAS's drugs address?

BioMAS's AS101/SAS drugs have shown preclinical and clinical efficacy for autoimmune-inflammatory diseases (such as psoriasis, arthritis, Crohn's, and MS), certain viral conditions (HPV warts), angiogenesis-related diseases (AMD), thrombocytopenia, neutropenia, and fertility preservation following chemotherapy and radiotherapy.

When was BioMAS founded?

BioMAS was founded in September 2000.

What was a significant corporate event for BioMAS in March 2014?

In March 2014, Cosmo Pharmaceuticals acquired a 15.4% stake in BioMAS for ILS 7 million.